Related Experiment Video
Updated: Jun 13, 2025
Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
Spectroelectrochemical studies of TDMQ20: A potential drug against Alzheimer's disease
Magdalena Z Wiloch1, Martin Perez-Estebanez2, Natalia Baran1
1Institute of Physical Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland.
Abstract:
Alzheimer's Disease (AD), reported for the first time in 1906, is a common disease that remains incurable to this day. In the past, a family of treatments using Cu(II) chelators failed during clinical trials, evidencing the importance of pre-clinical studies. In this work, we performed electrochemical characterisation of TDMQ20, a new potential drug against AD, using electrochemistry and spectroelectrochemistry. On the basis of voltammetry, we determined that TDMQ20 undergoes a two-step irreversible oxidation process and a one-step irreversible reduction process. Both oxidation and reduction reactions are pH-sensitive. Bidimensional UV-Vis spectroelectrochemistry (UV-Vis-SEC) allowed us to confirm that oxidation of TDMQ20 can occur both on the aliphatic chain and on the aromatic ring. The results expand the knowledge of the TDMQ20 redox activity in the human body which is important from the point of view of the toxicity of the proposed therapy.
Insights
Researchers studied TDMQ20, a potential Alzheimer's Disease (AD) drug, using electrochemistry. Electrochemical characterization revealed its pH-sensitive redox activity, crucial for understanding its safety and efficacy in the human body.
Area of Science:
- Neuroscience
- Electrochemistry
- Medicinal Chemistry
Background:
- Alzheimer's Disease (AD) remains incurable, highlighting the need for novel therapeutic strategies.
- Previous Cu(II) chelator treatments for AD failed in clinical trials, emphasizing the importance of rigorous preclinical evaluation.
- Understanding drug redox activity is vital for assessing potential toxicity and therapeutic efficacy.
Purpose of the Study:
- To electrochemically characterize TDMQ20, a novel drug candidate for Alzheimer's Disease.
- To investigate the pH-dependent redox behavior of TDMQ20.
- To determine the sites of oxidation for TDMQ20 in a biologically relevant context.
Main Methods:
- Voltammetry was employed to determine the electrochemical processes of TDMQ20.
- Spectroelectrochemistry, specifically Bidimensional UV-Vis Spectroelectrochemistry (UV-Vis-SEC), was utilized.
- Electrochemical characterization was performed under varying pH conditions.
Main Results:
- TDMQ20 exhibits a two-step irreversible oxidation and a one-step irreversible reduction.
- Both oxidation and reduction processes are sensitive to changes in pH.
- UV-Vis-SEC confirmed that oxidation occurs on both the aliphatic chain and aromatic ring of TDMQ20.
Conclusions:
- The study provides a comprehensive electrochemical profile of TDMQ20.
- The identified redox activity and its pH-dependence are critical for predicting TDMQ20's behavior in vivo.
- This research contributes essential data for evaluating the safety and potential toxicity of TDMQ20 as an Alzheimer's therapy.
More Related Videos
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
06:22A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
Published on: September 3, 2021
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...